Stay updated on Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Sign up to get notified when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.

Latest updates to the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page
- Check5 days agoChange DetectedThe page's revision label changed from v3.6.2 to v3.6.3. This indicates a minor update to the page or its assets rather than a change to core content and user-facing features.SummaryDifference0.0%

- Check12 days agoChange DetectedThe page revision tag was updated from v3.6.0 to v3.6.2, indicating a minor build update. This update does not modify the study details or how users interact with the page.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page adds new navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and shows recruitment is closed. It also standardizes the Intervention/Treatment heading and updates the site revision from v3.5.5 to v3.6.0.SummaryDifference0.5%

- Check34 days agoChange DetectedThe study record was updated to Terminated and now includes a new Strategic considerations section; the Petah Tikva location was broadened to include the Central District, and enrollment dates moved from estimated to actual, with a new revision timestamp.SummaryDifference0.7%

- Check55 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous revision tag. This reflects a system-level update to the page without altering the study information.SummaryDifference0.0%

- Check62 days agoChange DetectedThe Taiwan site entry was updated from Taoyuan, Taiwan, 333 to Taoyuan City, Taiwan, 333, clarifying the exact city for this enrollment site. This change improves precision in the study's location listing for Taiwan.SummaryDifference0.0%

Stay in the know with updates to Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.